JAK2 V617F mouse bone marrow pathology testing provides comprehensive histopathological evaluation of murine models carrying the JAK2 V617F mutation, the most common driver mutation in myeloproliferative neoplasms (MPNs). Our testing service delivers standardized assessment of bone marrow cellularity, megakaryocyte proliferation, reticulin fibrosis grading, and immunophenotypic markers to support pathogenesis research and preclinical drug development. With validated staining protocols, expert pathologist interpretation, and digital image analysis, researchers obtain reproducible, publication-quality pathological data.
Technical Overview
The JAK2 V617F mutation, a somatic gain-of-function substitution of valine with phenylalanine at codon 617 of the Janus kinase 2 gene, is detected in more than 95% of patients with polycythemia vera and approximately 50% to 60% of patients with essential thrombocythemia and primary myelofibrosis. Murine models engineered to express the human-equivalent JAK2 V617F mutation, including transgenic, knock-in, and conditional expression systems, faithfully recapitulate key features of human myeloproliferative neoplasms, such as erythrocytosis, leukocytosis, thrombocytosis, splenomegaly, extramedullary hematopoiesis, and progressive myelofibrosis.
Bone marrow pathology testing in JAK2 V617F mice is the gold standard for characterizing disease progression and evaluating therapeutic interventions at the tissue level. Because the mutant hematopoietic clone drives distinctive histological changes, including panmyelosis, megakaryocytic clustering and atypia, and a progressive increase in reticulin fiber deposition, systematic histopathological analysis provides direct morphological evidence of disease phenotype and drug response that peripheral blood counts alone cannot reveal. Our testing platform integrates tissue processing, specialized staining, immunohistochemistry, semi-automated image quantification, and expert pathological interpretation into a standardized workflow compliant with research-grade quality standards.
Testing Samples
Bone Specimens
The femur is the preferred bone specimen because it offers a consistent longitudinal view of the marrow cavity and allows reliable cellularity assessment. The sternum, tibia, and vertebral column are acceptable alternatives or complementary samples. Intact bones should be harvested immediately after euthanasia, trimmed of adjacent soft tissue, and fixed whole to preserve marrow architecture. Decalcification is performed after adequate fixation to maintain staining quality and antigenicity.
Hematolymphoid Organs
Spleen and liver samples are strongly recommended as companion specimens. JAK2 V617F mice characteristically develop marked splenomegaly with splenic extramedullary hematopoiesis, and histological confirmation of splenic and hepatic hematopoietic infiltrates is an integral component of the MPN phenotype. Lymph nodes and lung tissue may be included when extramedullary hematopoiesis at additional sites is suspected.
Peripheral Blood and Marrow Aspirates
Peripheral blood collected via the retro-orbital sinus, submandibular vein, or cardiac puncture supports complete blood count analysis and blood smear morphology, which correlate with marrow findings. Bone marrow aspirate smears from the femur or iliac crest may be prepared for cytological evaluation of individual cell lineages, although histological sections remain the primary material for fibrosis assessment.
Genotyping Material
Tail snips, ear punches, or fresh marrow cells should be provided for PCR-based genotype confirmation of the JAK2 V617F allele, ensuring that pathological findings are correctly assigned to mutant, wild-type, or conditional knockout groups.
Testing Items
Core testing items are structured to capture the full spectrum of pathological changes driven by the JAK2 V617F mutation:
- Bone marrow cellularity quantification, expressed as the percentage of hematopoietic area occupied by cells versus fat or serous atrophy.
- Granulocytic hyperplasia assessment, including myeloid-to-erythroid ratio estimation and left-shift evaluation.
- Megakaryocyte enumeration, density calculation (cells per high-power field), clustering analysis, and nuclear atypia scoring.
- Myelofibrosis grading using a validated semi-quantitative reticulin grading scale from grade 0 to grade 3, modeled on human MPN grading criteria.
- Osteosclerosis evaluation, including trabecular bone volume measurement and endosteal bone thickening assessment.
- Splenic extramedullary hematopoiesis grading based on red pulp expansion and lineage composition.
- Hepatic hematopoiesis and sinusoidal infiltration assessment.
- Iron staining of marrow sections when iron store evaluation is required.
- Apoptosis and proliferation indices using cleaved caspase-3 and Ki-67 immunostaining.
- Optional molecular pathology confirmation of mutant allele burden in marrow-derived DNA.
Testing Methods
Tissue Fixation and Decalcification
Bones are fixed in 10% neutral buffered formalin for 24 to 48 hours under a consistent bone-to-fixative volume ratio. Gentle EDTA-based decalcification is the preferred method because it preserves nucleic acid integrity, protein antigenicity, and staining fidelity. Acid decalcification is available as a faster option but is applied only when downstream immunohistochemistry requirements permit.
Processing, Embedding, and Sectioning
Decalcified bones are processed through graded alcohols, cleared, and paraffin-embedded in a standardized orientation so that longitudinal sections through the growth plate and central marrow cavity are obtained. Sections are cut at 3 to 4 micrometers for routine staining and 4 to 5 micrometers for reticulin staining to ensure optimal fiber visualization.
Histochemical Staining
Hematoxylin and eosin staining is performed for comprehensive morphological evaluation. Gordon-Sweet or equivalent ammoniacal silver reticulin staining is used to visualize reticulin fiber networks and assign fibrosis grades. Masson's trichrome staining highlights collagen deposition and osteoid in advanced fibrotic and osteosclerotic lesions. Perls' Prussian blue staining is applied for iron store assessment when requested.
Immunohistochemistry
Validated antibodies reactive in paraffin-embedded murine tissue are used to characterize lineage composition. Commonly applied markers include CD41 or CD42b for megakaryocytes, MPO for granulocytic cells, Ter119 for erythroid cells, F4/80 for macrophages, and Ki-67 for proliferating cells. Heat-induced epitope retrieval and appropriate positive and negative controls are included in every run.
Digital Image Analysis and Pathologist Review
Whole-slide scanning enables digital quantification of cellularity, megakaryocyte density, fibrotic area, and trabecular bone volume using calibrated analysis software. All automated results are verified by a board-experienced veterinary or hematopathologist, and a comprehensive written report with representative photomicrographs, semi-quantitative scores, and interpretive conclusions is delivered.
Applications
JAK2 V617F mouse bone marrow pathology testing supports a wide range of translational research objectives:
- Phenotypic characterization of newly generated or newly acquired JAK2 V617F mouse lines, including disease onset, severity scoring, and age-dependent progression mapping.
- Preclinical efficacy evaluation of JAK inhibitors such as ruxolitinib, fedratinib, and pacritinib, using reticulin fibrosis regression and cellularity normalization as pharmacodynamic endpoints.
- Anti-fibrotic drug development studies targeting myelofibrosis, where serial reticulin grading quantifies therapeutic impact on stromal remodeling.
- Pathogenesis research into mutant hematopoietic stem cell behavior, inflammatory signaling, megakaryocyte-stroma interactions, and disease progression from prefibrotic to overt fibrotic stages.
- Combination therapy and dosing regimen optimization studies requiring objective, quantitative tissue-level outcome measures.
- Biomarker validation and companion diagnostic development, correlating histological endpoints with circulating cytokines, allele burden, and imaging parameters.
- Publication and regulatory submission support through standardized, reproducible, reviewer-ready pathological data.
FAQ
How should bone samples be prepared and shipped?
Freshly harvested bones should be placed immediately in at least a 10-fold volume of 10% neutral buffered formalin, fixed for 24 to 48 hours at room temperature, and shipped in sealed leak-proof containers at ambient temperature. Alternatively, already-fixed tissue can be transferred to 70% ethanol for shipping. Do not freeze specimens, as freeze-thaw artifacts severely compromise marrow morphology.
Why is EDTA decalcification recommended over acid decalcification?
EDTA chelates calcium without extracting proteins or degrading nucleic acids, thereby preserving high-quality H&E morphology, crisp reticulin staining, and reliable immunohistochemical reactivity. Acid decalcification is faster but frequently causes antigen loss and staining artifacts, which can compromise interpretation of lineage markers in MPN studies.
What is the turnaround time for a standard project?
Typical turnaround is 10 to 15 working days from sample receipt for routine H&E plus reticulin staining with pathologist review. Projects involving EDTA decalcification of large bones, extensive immunohistochemistry panels, or whole-slide scanning with digital quantification may require 15 to 20 working days. Expedited processing can be arranged for time-sensitive studies.
Can reticulin fibrosis grading in mice be directly compared with human myelofibrosis grading?
Yes. We apply a semi-quantitative grading framework adapted from the European consensus criteria used in human MPN, with mouse-specific calibration for trabecular architecture and baseline reticulin levels. This approach enables meaningful cross-species comparison while accounting for anatomical differences between murine and human bone marrow.
How many animals per group are recommended for statistical analysis?
For fibrosis grading and cellularity endpoints, we generally recommend a minimum of 5 to 8 mice per group to achieve adequate statistical power, accounting for the inherent inter-animal variability of the JAK2 V617F phenotype. Including age- and sex-matched wild-type littermate controls is essential for valid baseline comparison.
Is genotyping confirmation included in the service?
PCR-based confirmation of the JAK2 V617F allele can be included as an add-on item when tail tissue or fresh marrow cells are supplied. Genotype confirmation before pathological analysis is strongly recommended to eliminate sample misassignment risk in conditional and Cre-dependent models.
What deliverables are provided in the final report?
The final report includes H&E and special staining results, reticulin fibrosis grades, megakaryocyte density and clustering data, cellularity measurements, immunohistochemistry scoring, whole-slide digital images, representative high-resolution photomicrographs, group-level statistical summaries, and a written pathological interpretation by a qualified pathologist.
